Paul G. Allen Frontiers Group    [to 6 Apr 2019]
No new digest content identified.
BMGF – Gates Foundation  [to 6 Apr 2019]
No new digest content identified.
Bill & Melinda Gates Medical Research Institute    [to 6 Apr 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
CARB-X   [to 6 Apr 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
CEPI – Coalition for Epidemic Preparedness Innovations  [to 6 Apr 2019]
29 Mar 2019
The woman who helped to stop an Ebola epidemic in Nigeria
By Niniola Soleye
In 2014-2016, West Africa experienced the largest Ebola outbreak to date. Thanks to the heroic work of Dr Ameyo Stella Adadevoh and others, Nigeria steered clear of what could have been a very deadly outbreak of the disease. Tragically Dr Adadevoh lost her life to Ebola, but her legacy lives on today through the Dr Ameyo Stella Adadevoh Health Trust…

29 Mar 2019 – Comment
You can’t beat epidemics without equitable access to vaccines
By Richard Hatchett, CEPI CEO
We’re developing vaccines against emerging infectious diseases. Getting them to the people who need them, when they need them, regardless of ability to pay, is not just important for access, it’s the only way to beat epidemic… CEPI is 100% committed to equitable access. This commitment drives every aspect of our work and is key to our success as a global health organisation…

Clinton Health Access Initiative, Inc. (CHAI)  [to 6 Apr 2019]
No new digest content identified.

EDCTP    [to 6 Apr 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
Emory Vaccine Center    [to 6 Apr 2019]
No new digest content identified.
European Medicines Agency  [to 6 Apr 2019]
News and press releases
News: EU recommendations for 2019/2020 seasonal flu vaccine composition
European Vaccine Initiative  [to 6 Apr 2019]
Latest news
No new digest content identified.

FDA [to 6 Apr 2019]
April 03, 2019 –
Statement by FDA Commissioner Scott Gottlieb, M.D., and Biologics Center Director Peter Marks, M.D., Ph.D. on FDA’s continued efforts to stop stem cell clinics and manufacturers from marketing unapproved products that put patients at risk, while progressing the agency’s commitment to help advance legitimate stem cell product development under existing agency regulations
Fondation Merieux  [to 6 Apr 2019]
No new digest content identified.

Gavi [to 6 Apr 2019]
Latest News
03 April 2019
Cholera vaccination campaign begins in Mozambique
Following Cyclone Idai devastation, nearly 900,000 people will receive the vaccine from the Gavi-funded stockpile.
Geneva, 3 April 2019 – An oral cholera vaccination campaign to protect survivors of Cyclone Idai begins today in Beira, Mozambique. Funded by Gavi, the Vaccine Alliance, the campaign will be carried out by the Mozambique Ministry of Health, with support from the World Health Organization (WHO) and other partners, including UNICEF, the International Federation of the Red Cross and Red Crescent Societies (IFRC), Médecins Sans Frontières (MSF) and Save the Children.
There has already been one reported cholera death and almost 1,500 reported cases following the cyclone, which caused severe flooding in Mozambique, Zimbabwe, Malawi and Madagascar after making landfall in March. Nine cholera treatment centres, with 500-bed capacity, are already admitting patients.
“Cyclone Idai’s trail of devastation has left the city of Beira’s water and sanitation infrastructure in ruins, providing the perfect conditions for cholera to spread,” said Gavi CEO, Dr Seth Berkley. “This cyclone has already caused enough devastation and misery across south east Africa; we have to hope these vaccines will help stop a potentially major outbreak and prevent yet more suffering.”

02 Apr…il 2019
Japan to host major event to boost vaccination in world’s poorest countries
Opportunity to save lives through immunisation to be unveiled at the Tokyo International Conference on African Development (TICAD) 7
Geneva, 2 April 2019 – Japan will host a launch meeting for Gavi’s third replenishment at August’s TICAD 7 in Yokohama that will set out how Gavi, the Vaccine Alliance, on the eve of its 20th anniversary, will continue its work vaccinating millions of children in the world’s poorest countries.
“Japan has been a strong supporter of our mission for many years and we’re delighted they have offered to host this milestone event,” said Dr Seth Berkley, CEO of Gavi. “The core aim of TICAD – to help build a healthy and prosperous Africa – couldn’t be closer to Gavi’s mission. Vaccines are a crucial platform for primary health care, which is itself a cornerstone of universal health coverage. They also prevent the diseases that stop children going to school and finding work later in life. Vaccines not only build healthy societies, they build healthy economies.”
The Japanese government has supported Gavi since 2011, providing about US$ 130 million in the years since for Gavi’s programmes around the world…

GHIT Fund [to 6 Apr 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
Global Fund [to 6 Apr 2019]
No new digest content identified.
Hilleman Laboratories [to 6 Apr 2019]
No new digest content identified.
Human Vaccines Project [to 6 Apr 2019]
No new digest content identified.

IAVI [to 6 Apr 2019]
No new digest content identified.

1 April 2019
​Moody’s  Investors Service has today assigned a Aa1 senior unsecured rating (outlook stable) to the trust certificate issued by IFFIm Sukuk Company III Limited (“the Issuer”), a special purpose vehicle established in the Cayman Islands by the International Finance Facility for Immunisation (IFFIm).

IFRC   [to 6 Apr 2019]
Selected Press Releases, Announcements
Iran, Middle East and North Africa
“Iran is under water” – IFRC announces support as flood crisis worsens
Beirut/Geneva, 3 April 2019 – As the flooding emergency in Iran worsens, the world’s largest humanitarian network has released just under 500,000 Swiss francs to bolster local Red Crescent relief efforts. The funds released from IFRC’s Disaster Relief …
3 April 2019


Africa, Mozambique
Mozambique: Aid reaches community cut off since cyclone
Beira/Geneva, 3 April 2019 – More than 2,300 people isolated since Cycone Idai struck Mozambique received a major delivery of Red Cross emergency supplies late yesterday. The community of Buzi, which lies to the south of the city of Beira, had been alm …
3 April 2019


Europe, Middle East and North Africa
Red Cross Red Crescent Mediterranean National Societies to tackle cross-cutting migration issues
More than 150 Red Cross Red Crescent delegates from 23 countries bordering the Mediterranean Sea are meeting in Sarajevo this week to discuss approaches to aiding vulnerable migrants and the communities receiving them.
2 April 2019


IVAC  [to 6 Apr 2019]
No new digest content identified.


IVI   [to 6 Apr 2019]
IVI News & Announcements
No new digest content identified.


JEE Alliance  [to 6 Apr 2019]
Selected News and Events
No new digest content identified.
MSF/Médecins Sans Frontières  [to 6 Apr 2019]
Selected News; Project Updates, Reports [as presented on website]
Rwandan genocide 25 years on: MSF caught in spiral of extreme violence from Rwanda to Zaire
Voices from the Field 5 Apr 2019

Cyclone Idai & Southern Africa flooding
MSF emergency response to Cyclone Idai and flooding
Crisis Update 5 Apr 2019

Gaza’s numbing routine of injury and death
Voices from the Field 4 Apr 2019

Violence, humanitarian needs and fear mount in Diffa
Project Update 4 Apr 2019

Over 30,000 people in acute need in northern Borno state
Press Release 4 Apr 2019

Medical admissions in Aden suspended after patient kidnapped and killed
Press Release 4 Apr 2019

DRC 2018 Ebola outbreaks
Crisis update – April 2019
Crisis Update 3 Apr 2019

Triaging patients in one of Baghdad’s busiest emergency departments
Voices from the Field 2 Apr 2019

Migrants in Libya: “We were able to make their time in that horrible place slightly better.”
Voices from the Field 2 Apr 2019
NIH  [to 6 Apr 2019]
April 4, 2019
Scientists explore new roles for RNA
— Cells use RNA to communicate; researchers may be able to translate this information into clinical applications.

FDA-approved drug effectively treats rare chronic immune disorder
April 3, 2019 — Small NIH clinical trial conducted in partnership with AstraZeneca [hypereosinophilic syndromes (HES)].

Opioid epidemic is increasing rates of some infectious diseases
April 3, 2019 —
Health, substance use professionals must work together to thwart public health crisis.
The United States faces a converging public health crisis as the nation’s opioid epidemic fuels growing rates of certain infectious diseases, including HIV/AIDS, hepatitis, heart infections, and skin and soft tissue infections. Infectious disease and substance use disorder professionals must work together to stem the mounting public health threat, according to a new commentary in the Journal of Infectious Diseases

NIH begins first-in-human trial of a universal influenza vaccine candidate
April 3, 2019 —
Investigational vaccine [H1ssF_3928] designed to provide broad, durable protection from flu.
…The clinical trial is being conducted at the NIH Clinical Center in Bethesda, Maryland. It is being led by Grace Chen, M.D., of NIAID’s Vaccine Research Center (VRC) Clinical Trials Program. The trial will gradually enroll at least 53 healthy adults aged 18 to 70 years. The first five participants will be aged 18 to 40 years and will receive a single 20-microgram (mcg) intramuscular injection of the experimental vaccine. The remaining 48 participants will receive two 60-mcg vaccinations spaced 16 weeks apart. They will be stratified by age into four groups of 12 people each: 18 to 40 years, 41 to 49 years, 50 to 59 years, and 60 to 70 years. Investigators hope to understand how participants’ immune responses to the experimental vaccine may vary based on age and the likelihood of their previous exposure to different influenza variants…

Acute flaccid myelitis requires galvanized research response
April 2, 2019 — NIH experts review puzzling muscle paralysis condition in children.


New $22 Million Project Targets Deadly Viruses
BRONX, N.Y., April 4, 2019 /PRNewswire/ — The National Institute of Allergy and Infectious Diseases (NIAID) has awarded an international consortium led by Albert Einstein College of Medicine, part of Montefiore, a five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.

The viruses are the tick-borne Crimean-Congo hemorrhagic fever virus (CCHFV) and three hantaviruses, which are spread by rodents: Andes virus (ANDV), Sin Nombre virus (SNV), and Puumula virus (PUUV). The NIAID has designated all but PUUV as Category A agents—emerging infectious diseases or pathogens that pose the highest risk to national security and public health.

The project, called the Prometheus Center for Excellence in Translational Research (Prometheus), focuses on viruses that spread from animals to people. It builds on a 2017 study involving ebolaviruses, believed to spread to people from fruit bats or primates. In addition to Einstein, the participating institutions leading the project are the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Mapp Biopharmaceutical, Inc., The University of Texas at Austin, and Adimab, LLC, a biotech company…


PATH  [to 6 Apr 2019]
April 2, 2019 by PATH
New report by PAHO and PATH details strategies to improve vaccine programs through effective data use
[See Milestones above for detail]


Sabin Vaccine Institute  [to 6 Apr 2019]
Tuesday, April 2, 2019
Dr. Carol Baker Receives 2019 Albert B. Sabin Gold Medal
Washington, D.C. – The Sabin Vaccine Institute (Sabin) today announced it will present its annual Albert B. Sabin Gold Medal to Dr. Carol J. Baker, whose groundbreaking research in group B Streptococcus (GBS) is accelerating progress toward a much-needed vaccine to prevent a bacterial infection that can cause lifelong illness or death in newborns.


UNAIDS [to 6 Apr 2019]
Selected Press Releases/Reports/Statements
2 April 2019
Helping the forgotten generation  [Burkina Faso,]

2 April 2019
Learning lessons on evaluation  [UNAIDS’ first consultation on evaluation]

1 April 2019
Key populations are being left behind
In 2017, approximately 47% of new HIV infections globally were among key populations and their sexual partners.
Members of key populations are at a significantly higher risk of contracting HIV. The available data suggest that the risk of HIV acquisition among gay men and other men who have sex with men was 28 times higher in 2017 than it was among heterosexual men. Similarly, the risk of acquiring HIV for people who inject drugs was 22 times higher than for people who do not inject drugs, 13 times higher for female sex workers than adult women aged 15–49 years and 13 times higher for transgender women than adults aged 15–49 years.


UNICEF  [to 6 Apr 2019]
News note
Venezuela crisis: UNICEF ramps up support for children and families amidst electricity blackouts

Press release
Venezuela migrant crisis: 1.1 million children across the region will need assistance in 2019, up from nearly half a million today – UNICEF
UN children’s agency calls on host and transit countries to protect uprooted children from discrimination and ensure access to essential services

Press release
Opening Remarks by Henrietta Fore, UNICEF Executive Director, At opening of Sanitation and Water for All Sector Ministers’ Meeting San José, Costa Rica April 4, 2019

Press release
Islamic Development Bank and UNICEF to establish a Global Muslim Philanthropy Fund for Children

Only quality education and an end to violence can offer hope and better opportunities for children in Honduras
Statement by UNICEF Executive Director Henrietta Fore following visit to Honduras

Press release
1 in 4 health care facilities lacks basic water services – UNICEF, WHO
[See Milestones above for detail]

Press release
Cyclone Idai: 900,000 cholera vaccine doses arrive in Beira, Mozambique
Nearly 900,000 doses of the cholera vaccine, procured by UNICEF and the World Health Organization (WHO), arrived in Beira, Mozambique, on Tuesday afternoon and the vaccination campaign will begin imminently. The vaccines are funded by Gavi, The Vaccine Alliance.
Mozambique’s Ministry of Health has confirmed 1,052 cases of cholera in the aftermath of Cyclone Idai. The vast majority of these (959 cases) are in Beira where one death has also been confirmed, followed by Nhamatanda (87 cases). The disease is spreading rapidly…

Vaccine Confidence Project [to 6 Apr 2019]
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 6 Apr 2019]
No new digest content identified.

Wellcome Trust [to 6 Apr 2019]
No new digest content identified.

The Wistar Institute   [to 6 Apr 2019]
Press Release   Apr. 5, 2019
Synthetic DNA-encoded Antibodies Against Zika Virus Shown to be Effective in Preclinical Studies
The DNA-encoded monoclonal antibody platform provides rapid and sustained protection against Zika virus infection.
World Organisation for Animal Health (OIE) [to 6 Apr 2019]
No new digest content identified.


BIO [to 6 Apr 2019]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 6 Apr 2019]
No new digest content identified.

IFPMA [to 6 Apr 2019]
No new digest content identified.

PhRMA [to 6 Apr 2019]
No new digest content identified.